Publications by authors named "M E Castellanos"
Background: Transmission of requires adequate contact between an infectious case and a susceptible host. The aim of this analysis was to validate a recently developed contact score that assessed settings of exposure and relationships between the case and contact.
Methods: In a cross-sectional study from Kampala, Uganda, we estimated the prevalence of tuberculous infection (TBI) in social contacts of adult TB cases according to the setting and relationship domains of the contact score.
The blood enzyme glutamate-oxaloacetate transaminase (GOT) has been postulated as an effective therapeutic to protect the brain during stroke. To demonstrate its potential clinical utility, a new human recombinant form of GOT (rGOT) was produced for medical use. We tested the pharmacokinetics and evaluated the protective efficacy of rGOT in rodent and non-human primate models that reflected clinical stroke conditions.
View Article and Find Full Text PDFArticle Synopsis
- A comprehensive understanding of the healthcare system and neurology departments is essential for effectively implementing anti-amyloid antibody treatments in hospitals, especially regarding the organization and patient care.* -
- A survey of department heads from 16 Spanish hospitals showed consensus on the need for structural changes, such as focusing Alzheimer’s patients in specialized dementia units and expanding neurology services by hiring more staff and enhancing diagnostic procedures.* -
- The findings underscore the necessity for significant transformations in Spanish neurology departments to ensure the successful integration of anti-amyloid antibodies and promote fair access to new therapies for patients.*
Background: We describe the epidemiological and clinical characteristics of thrombosis with thrombocytopenia syndrome (TTS) cases reported in Spain.
Methods: We included all cases of venous or arterial thrombosis with thrombocytopenia following administration of adenoviral vector vaccines (AstraZeneca or Janssen) against COVID-19 disease between 1 February and 26 September 2021. We describe the crude rate and the standardised morbidity ratio.